Welcome to the new Independent website. We hope you enjoy it and we value your feedback. Please contact us here.

Business News

GSK in HIV drug deal with Shionogi

GlaxoSmithKline has beefed up its interest in an HIV drug which analysts regard as a potential multi-billion-dollar-a-year blockbuster.

A new deal with Shionogi sees Britain's biggest pharmaceuticals company give the Japanese drug maker a 10 per cent stake in Viiv Healthcare – an HIV drug joint venture set up in 2009 between GSK and Pfizer – in exchange for its rights to dolutegravir, a once-daily HIV medicine hich has performed well in clinical trials.

Previously, income from the medicine would have been shared 50/50 between Viiv and Shionogi, where now GSK will earn as much as 66 per cent from the drug.